<DOC>
	<DOCNO>NCT02592941</DOCNO>
	<brief_summary>The expanded access program provide access treatment deflazacort child , adolescent , adult patient DMD U.S. ineligible , unable , otherwise unwilling enroll clinical study examine efficacy deflazacort new drug application preparation review . Enrollment open eligible patient .</brief_summary>
	<brief_title>Deflazacort Expanded Access Program Children , Adolescents Adults With Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>Deflazacort supply free charge ship directly patient caregiver , appropriate . Treating physician continue follow standard care activity procedures management DMD . Treating physician participate expanded access program require collect/document patient caregiver report safety event report sponsor..</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Deflazacort</mesh_term>
	<criteria>Main Confirmed diagnosis Duchenne muscular dystrophy The patient â‰¥ 5 year old Current childhood vaccination include chicken pox vaccine Main History current medication condition could affect safety pose additional risk Hypersensitivity allergic reaction steroid formulation</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>